Kidney Cancer

Angiogenesis Inhibitor Lengthens Median Survival Two-Fold

Published in Cancer Weekly, April 10th, 2001

AEterna Laboratories, Inc. (AEL, AELA) reported on March 26, 2001, clinical data from a Phase I/II clinical trial, demonstrating a statistically significant two-fold increase (p<0.01) in median survival time for metastatic renal cell carcinoma (kidney cancer) patients refractory to standard treatments and who were administered a higher dose of its lead product, Neovastat/AE-941.

The median survival time of patients treated with a dose of 30 mL twice a day was 7.1 months, compared to 16.3 months for patients receiving a dose of 120 mL twice a day. A patient with metastatic renal cell carcinoma who does not respond to standard treatments is expected to...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2001-04-10)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry